Mumbai, May 28 -- Lupin today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Ankleshwar facility in Gujarat, India, following closure of a product specific Pre-Approval Inspection from 02 March to 07 March 2026.

Published by HT Digital Content Services with permission from Capital Market....